CG
ENTA icon

Cutler Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Cutler Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,820
Closed -$83K – 4968
2020
Q3 		$83K Buy
1,820
+520
+40% +$25.2K 0.01% 1439
2020
Q2 		$65K Buy
+1,300
New +$67.3K ﹤0.01% 1581
2019
Q2 		– Sell
-1,400
Closed -$133K – 4366
2019
Q1 		$133K Buy
1,400
+1,300
+1,300% +$117K 0.01% 850
2018
Q4 		$7K Hold
100
– – ﹤0.01% 2733
2018
Q3 		$8K Sell
100
-500
-83% -$50.1K ﹤0.01% 2769
2018
Q2 		$69K Buy
600
+50
+9% +$4.99K 0.01% 1394
2018
Q1 		$44K Buy
+550
New +$42.3K ﹤0.01% 1740
2017
Q4 		– Sell
-14
Closed – – 5130
2017
Q3 		$0 Sell
14
-186
-93% -$7.48K ﹤0.01% 6048
2017
Q2 		$7K Buy
+200
New +$6.4K ﹤0.01% 4505
2016
Q4 		– Sell
-100
Closed -$2.87K – 6694
2016
Q3 		$2K Sell
100
-4,200
-98% -$97.5K ﹤0.01% 5672
2016
Q2 		$94K Buy
4,300
+3,520
+451% +$92.1K ﹤0.01% 1739
2016
Q1 		$22K Sell
780
-2,000
-72% -$55.7K ﹤0.01% 3165
2015
Q4 		$91K Buy
+2,780
New +$90.6K 0.01% 1872

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cutler Group's ENTA Position: Q4 2020 in Review

Cutler Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 1,820 shares — an estimated $83K sold.

Cutler Group first reported a position in ENTA in Q4 2015 and held it in 13 quarters. The position peaked at $133K in Q1 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Cutler Group reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cutler Group sold 1,820 Enanta Pharmaceuticals shares in Q4 2020, an estimated $83K.
  • Cutler Group first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Enanta Pharmaceuticals position peaked at $133K in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.